Pharmacokinetics of Dolutegravir in a Premature Neonate after HIV Treatment Intensification during Pregnancy
Open Access
- 1 June 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (6), 3660-3662
- https://doi.org/10.1128/aac.00173-15
Abstract
We describe the pharmacokinetics of dolutegravir (DTG) in a premature neonate after maternal intensification of an antiretroviral (ARV) regimen by adding DTG. During the last 2 weeks of pregnancy, the ARV was tenofovir-emtricitabine, atazanavir-ritonavir, and DTG (50 mg once daily). From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults.This publication has 5 references indexed in Scilit:
- Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next‐generation HIV integrase inhibitor, S/GSK1349572British Journal of Clinical Pharmacology, 2011
- The Development of UDP-Glucuronosyltransferases 1A1 and 1A6 in the Pediatric LiverDrug Metabolism and Disposition, 2011
- Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.Current HIV Research, 2009
- Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancyJournal of Pharmaceutical Sciences, 2009
- Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography–tandem mass spectrometryBiomedical Chromatography, 2007